Other symptoms could include numbness or tingling in your hands and feet, constipation, anemia, and problems with balance and memory
Originally, Glucagon-like peptide-1 (GLP-1) was used only for the treatment of Type 2 diabetes, but after clinical trials showed significant signs of weight loss, semaglutide and tirzepatide were approved for weight loss by the National Institute for Health and Care Excellence (NICE) in October 2023
Mounjaro skin sensitivity may affect the injection area or, in some cases, larger parts of the body
Typical ranges: BPC-157 at 250 to 750 mcg/day, semaglutide at 0.25 to 2.4 mg/week, CJC-1295 at 100 to 200 mcg per injection, and TB-500 at 2 to 5 mg twice weekly
Cent Eur J Chem
2 , 3 There is a higher prevalence in women